Hinge Health Q3 2026 Earnings Call - HINGE HEALTH INC

Financial Performance:

• Q3 2026 revenue reached $235 million, representing a 52% year-over-year increase.
• Last 12 months (LTM) calculated billings rose 54% YoY to $960 million.
• Gross margin expanded to 88%, an improvement of 480 basis points YoY, driven by reduced hardware costs and AI automation efficiencies.
• Operating income was $77 million, yielding a 33% operating margin (up 1,300 basis points YoY).
• Free cash flow for the quarter was $120 million (51% margin), excluding $7 million in one-time acquisition payments.
• Operating expenses declined to 55% of revenue from 63% in the prior year, reflecting strong leverage.
• Diluted net income per share was $0.71 with a weighted average diluted share count of 86.5 million.
• Cash and investments ended the quarter at $358 million; $26 million was spent on share repurchases.

Guidance and Future Outlook:

• Q4 2026 revenue guidance raised to $249–$251 million (midpoint 46% growth YoY); operating income guided at $81–$83 million (33% margin).
• Full-year 2026 revenue guidance raised to $879–$881 million (midpoint 50% growth YoY); full-year operating income guided at $266–$288 million (30% midpoint margin).
• Year-end eligible lives expected to reach ~25.5 million (up 0.5 million from prior guidance), including Cylinder's net new lives.
• Full-year yield expected to improve to 4.6% (from 4.45%), driven by higher engagement and retention.
• ASPs are projected to remain flat for 2026 and 2027, with potential uplift expected in late 2027/2028 as new programs scale.
• Long-term goal to achieve 35%+ operating margins; 2026 midpoint targets 30% margin.

Business Segments and Product Lines:

• Core MSK: Remains the primary revenue driver; "Movement Analysis" (True Motion tech) is driving higher adherence via real-time progress tracking.
• Hinge Select (Surgery): Launched June; features a precision network of ~5,500 provider locations. Lives on Hinge Select have doubled since Investor Day.
• Migraine Care: In early access; early data shows 23% reduction in monthly migraine days and 28% reduction in attack duration. ~800 clients have access; 9 million lives targeted for launch in early 2027.
• GI Care: Integrated program targeting summer 2027 launch; leverages Cylinder acquisition. Features AI food/stool analysis and multidisciplinary teams. GI client base grew 40% since August acquisition announcement.
• SMB Segment: Closed nearly 1 million lives in 2026; characterized by faster sales cycles and higher yields compared to enterprise.
• Multi-product Adoption: Over 10 million lives across 800+ clients are accessing multiple products (MSK, Migraine, GI, Select).

Market and Competitive Landscape:

• Added three new Fortune 15 clients and expanded one to full population coverage.
• Win rates are trending upward; clients are switching from competitors in record numbers due to clinical outcomes and ROI.
• SMB penetration is accelerating with 60+ ecosystem partners; early-mover advantage evident in default/opt-out models.
• Hinge Health reports 88% of target market lives remain untapped in the MSK space.
• Health plan and TPA retention is 100%; partners increasingly list Hinge as a preferred provider.

Risks and Challenges:

• Gross margin is expected to stabilize around 85% in 2027 as the company invests in care team staffing to meet demand, rather than exceeding 2026 levels.
• New product lines (Migraine, GI) will not meaningfully impact ASPs or billable activity until 2028.
• Integration of Cylinder's GI program into the unified platform must be completed by Summer 2027 to drive full revenue recognition.
• Market saturation in MSK remains a long-term consideration, though current penetration is minimal.

Management Commentary and Tone:

• CEO Daniel Perez noted strong momentum, citing the "triple aim" (clinical outcomes, cost reduction, member experience) as a growth catalyst.
• President Jim Pursley announced he is stepping down as President at year-end to focus on family but will remain on the Board; he praised his successor, Aaron Peer.
• CCO Aaron Peer highlighted the "insatiable demand" from clients and members, validating the product-market fit.
• CFO James Budge emphasized disciplined spending and the durability of yield improvements.
• Tone was confident and optimistic, with leadership expressing pride in the scale of profitability and growth achieved simultaneously.

Analyst Questions and Answers:

• Hinge Select: Confirmed strong surgeon reception due to pre-qualification and integrated hybrid care; network expansion is geographically targeted rather than density-focused.
• Yield Drivers: Cited 75% YoY increase in clinically targeted enrollment campaigns and 25% increase in member renewals (retention) as key structural improvements.
• Gross Margins: Company expects 85% gross margin in 2027; further efficiency gains will target operating margins.
• SMB Economics: Higher margins and faster sales cycles noted; yield improvements in SMB are outpacing enterprise.
• Hardware Strategy: Reaffirmed commitment to hardware for care automation; strategy is to build organically first, using M&A only for technology tuck-ins that accelerate timelines.
• Client Retention: Employer engagement in marketing correlates with ROI; strong outcomes drive high NPS and client trust for broader communication.
• 2027 Launches: Clarified that while verbal agreements for 2027 lives are strong, final contracts occur late in the year; launches will spread across Q1 2027 rather than solely on Jan 1.

Other Key Points:

• Hinge Health views its platform as "extensible," allowing efficient expansion into neurology and GI by leveraging the same AI intake and automated care delivery engine used in MSK.
• The company reports that 1 in 2 people with GI conditions also have MSK pain, and 70% of migraine sufferers have GI conditions, reinforcing the value of a unified care approach.
• The SMB segment is viewed as a significant under-penetrated market with faster yield ramp-up potential.
• The company expects to publish detailed clinical results for the Migraine program later in the year.
• Share count for 2026 and 2027 is expected to remain in the 85–87 million range.